Hansoh Pharmaceutical Group Company Limited (HK:3692)
:3692
Top Page
Hansoh Pharmaceutical Group Company Limited
(3692)
Select Model
Select Model
Rating:78Outperform
Price Target:
HK$45.00
▲(14.33% Upside)
Action:ReiteratedDate:11/15/25
Hansoh Pharmaceutical's overall stock score of 78 is driven primarily by its strong financial performance (score: 85, weight: 0.5), reflecting robust profitability, minimal debt, and solid cash flow growth. Technical analysis (score: 75, weight: 0.3) supports a bullish outlook with positive momentum, though a high Stochastic value signals potential short-term risks. Valuation (score: 60, weight: 0.2) tempers the score due to a high P/E ratio, indicating possible overvaluation.
Positive Factors
Revenue Growth
Consistent revenue growth highlights the company's expanding market reach and effective product adoption, particularly in key therapeutic areas.
Negative Factors
Cash Flow Concerns
Lack of operating and free cash flow may hinder the company's ability to fund operations and growth initiatives, posing a risk to financial health.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth highlights the company's expanding market reach and effective product adoption, particularly in key therapeutic areas.
Read all positive factors
Hansoh Pharmaceutical Group Company Limited (3692) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$238.33B
Dividend Yield0.97%
Average Volume (3M)9.67M
Price to Earnings (P/E)12.9
Beta (1Y)0.61
Revenue Growth8.68%
EPS Growth0.82%
CountryHK
Employees8,989
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.46
Shares Outstanding6,055,150,000
10 Day Avg. Volume6,926,281
30 Day Avg. Volume9,666,344
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)3.36
Price to Sales (P/S)7.85
P/FCF Ratio26.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$45.72Price Target Upside16.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.97
Revenue Forecast (FY)HK$16.77B
Hansoh Pharmaceutical Group Company Limited Business Overview & Revenue Model
Company Description
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic are...
How the Company Makes Money
Hansoh Pharmaceutical generates revenue through multiple streams, primarily by selling its pharmaceutical products to hospitals, pharmacies, and healthcare providers in China and internationally. The company’s key revenue drivers include sales of ...
Hansoh Pharmaceutical Group Company Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
80
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.19B | 12.26B | 10.10B | 9.38B | 9.94B | 8.69B |
| Gross Profit | 11.98B | 11.16B | 9.07B | 8.51B | 9.06B | 7.89B |
| EBITDA | 4.79B | 4.28B | 4.20B | 2.93B | 3.08B | 2.99B |
| Net Income | 4.78B | 4.37B | 3.28B | 2.58B | 2.71B | 2.57B |
Balance Sheet | ||||||
| Total Assets | 35.07B | 31.66B | 33.04B | 30.00B | 27.16B | 20.79B |
| Cash, Cash Equivalents and Short-Term Investments | 27.12B | 23.39B | 24.86B | 21.63B | 18.94B | 13.73B |
| Total Debt | 116.86M | 117.89M | 4.30B | 4.38B | 3.83B | 92.75M |
| Total Liabilities | 3.97B | 2.98B | 7.24B | 7.35B | 7.13B | 2.92B |
| Stockholders Equity | 31.10B | 28.68B | 25.79B | 22.65B | 20.03B | 17.88B |
Cash Flow | ||||||
| Free Cash Flow | 1.06B | 3.64B | 2.90B | 2.47B | 2.12B | 962.83M |
| Operating Cash Flow | 1.18B | 3.86B | 3.12B | 2.74B | 2.58B | 2.39B |
| Investing Cash Flow | -3.76B | -1.39B | 1.07B | -5.94B | -2.26B | -2.87B |
| Financing Cash Flow | -1.87B | -6.07B | -753.70M | -818.14M | 3.42B | -1.04B |
Hansoh Pharmaceutical Group Company Limited Technical Analysis
Positive
39.36
Price Trends
35.52
Positive
37.58
Positive
36.08
Positive
Market Momentum
0.21
Negative
70.67
Negative
95.97
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3692, the sentiment is Positive. The current price of 39.36 is above the 20-day moving average (MA) of 33.39, above the 50-day MA of 35.52, and above the 200-day MA of 36.08, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 70.67 is Negative, neither overbought nor oversold. The STOCH value of 95.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3692.
Hansoh Pharmaceutical Group Company Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$238.33B | 12.89 | 16.09% | 0.97% | 8.68% | 0.82% | |
73 Outperform | HK$25.63B | 22.15 | 7.26% | 3.13% | 10.56% | -13.58% | |
70 Outperform | HK$31.78B | 11.61 | 14.47% | 4.09% | -0.45% | 9.00% | |
61 Neutral | HK$39.39B | 6.37 | 7.91% | 2.95% | ― | ― | |
59 Neutral | HK$40.60B | 8.90 | 7.89% | 7.15% | 1.13% | -13.53% | |
57 Neutral | HK$75.74B | 14.15 | 7.02% | 1.69% | -1.12% | 76.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3692
Hansoh Pharmaceutical Group Company Limited
39.36
18.94
92.75%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
17.21
2.04
13.48%
HK:1513
Livzon Pharmaceutical Group
29.20
4.54
18.40%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
20.80
7.91
61.39%
HK:3320
China Resources Pharmaceutical Group Ltd.
6.27
1.70
37.08%
HK:0512
Grand Pharmaceutical Group Limited
7.22
1.88
35.21%
Hansoh Pharmaceutical Group Company Limited Corporate Events
Hansoh Pharma Wins Fifth China Approval for Flagship Lung Cancer Drug Ameile
Jan 8, 2026
Hansoh Pharmaceutical announced that its innovative lung cancer drug Ameile (aumolertinib mesylate tablets) has received approval from China’s National Medical Products Administration for a fifth indication, allowing its use in combination w...
Hansoh Pharma Licenses Hengrui’s Late-Stage Kidney Drug SHR6508 for China
Dec 28, 2025
Hansoh Pharmaceutical Group has signed a license agreement with Jiangsu Hengrui Pharmaceuticals to obtain exclusive rights to develop, manufacture and commercialise SHR6508 in mainland China, excluding Hong Kong, Macau and Taiwan. SHR6508, an allo...
Hansoh Pharma Adds Veteran Lawyer Yan Jia to Board, Bolsters Governance Committees
Dec 28, 2025
Hansoh Pharmaceutical Group has appointed veteran corporate lawyer Yan Jia as an independent non-executive director effective 26 December 2025, adding a seasoned legal and governance specialist with extensive China and international capital market...
Hansoh Pharmaceutical Details Board Composition and Committee Roles
Dec 28, 2025
Hansoh Pharmaceutical Group Company Limited has announced the current composition of its board of directors, comprising three executive directors led by chairlady and chief executive officer Zhong Huijuan, and four independent non-executive direct...
Hansoh Pharma Enters Global Licensing Agreement with Glenmark for Aumolertinib
Dec 16, 2025
Hansoh Pharmaceutical Group Company Limited announced a license agreement with Glenmark Specialty S.A. for the development and commercialization of Aumolertinib in various global regions. This agreement, which includes upfront and potential milest...
Hansoh Pharmaceutical Advances with New Drug Inclusions in 2025 NRDL
Dec 7, 2025
Hansoh Pharmaceutical Group Company Limited announced that two new indications of its drug Ameile have been added to the 2025 National Reimbursement Drug List (NRDL), while all indications of its drugs Saint Luolai and Hengmu have been renewed. Th...
Hansoh Pharmaceutical’s New Drug Application for Lung Cancer Treatment Accepted
Oct 23, 2025
Hansoh Pharmaceutical Group Company Limited announced that its New Drug Application for HS-10365 capsules, a RET inhibitor for treating RET fusion-positive non-small cell lung cancer, has been accepted by China’s National Medical Products Ad...
Hansoh Pharmaceutical Partners with Roche for Global Cancer Drug Development
Oct 16, 2025
Hansoh Pharmaceutical Group has entered into a license agreement with F. Hoffmann-La Roche Ltd, granting Roche an exclusive worldwide license to develop, manufacture, and commercialize Hansoh’s investigational CDH17-targeting antibody-drug c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.